Last reviewed · How we verify
NCT05419336: CGDEL
Child Growth and Development in East London
trial in Stunted Growth in 558 participants. Completed in 30 September 2024.
30 March 2024
Quick facts
| Lead sponsor | Queen Mary University of London |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 558 |
| Start date | 15 July 2022 |
| Primary completion | 30 March 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Stunted Growth — all drugs for Stunted Growth →
- Stunting — all drugs for Stunting →
- Growth Disorders — all drugs for Growth Disorders →
- Child Development — all drugs for Child Development →
Sponsor
Queen Mary University of London
Who can join
Adults 24 Months to 30 Months, any sex, with Stunted Growth or Stunting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overarching objective of this research is to detect poor growth and delayed development early in childhood by developing an automated growth-screening algorithm. The screening algorithm will be created using cohort data and piloted for feasibility and acceptability in Tower Hamlets. The ultimate goals are to detect linear growth failure and delayed development early to identify two groups of children: first, children with serious underlying medical disorders, in whom earlier diagnosis and management would improve clinical outcomes; and second, children whose poor growth and/or delayed development is a manifestation of socioeconomic disadvantage, in whom targeted pre-school interventions may improve long term health and education outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05419336
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Queen Mary University of London trials
Trials by the same sponsor.
- NCT07246005 — LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus · Phase 2 · not yet recruiting
- NCT07165678 — CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2) · NA · not yet recruiting
- NCT06937372 — Delivery and Implementation of a Randomised Crossover Trial on Thrombosis · NA · not yet recruiting
- NCT06600438 — Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial · NA · not yet recruiting
- NCT06987045 — Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05419336 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Queen Mary University of London
- Last refreshed: 20 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05419336.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing